A novel framework for separating normal and pathological high-frequency oscillations in animals with epilepsy uncovers new mechanisms for impaired hippocampal network function.

Acute one-hour treatment of Pik3ca mutant mice with a novel anti-epilepsy drug suppresses seizures despite continued developmental brain dysmorphology, promising a new therapeutic strategy for patients with intractable pediatric epilepsy.

Targeting reductions in prefrontal PV interneuron activity and gamma power during cue presentation can rescue attention impairments in a mouse model of absence epilepsy.

Non-invasive imaging of hippocampal neurodegeneration and structural reorganization during epileptogenesis allows the prediction of disease severity in mesial temporal lobe epilepsy, which may facilitate the early pharmacological intervention before seizure onset.

C. elegans EFHC1 influences neuronal transmission through the cilium and the synapse.

Optogenetic and electrical low-frequency stimulation in the sclerotic hippocampus prevents the emergence of spontaneous focal and evoked generalized seizures in a mouse epilepsy model.

Epilepsy caused by focal Pten deletion is only prevented when both mTOR complexes are simultaneously inhibited, but not alone, suggesting they play independent roles in the development of epilepsy.

Structural and binding studies provide insight into the molecular mechanism of protocadherin-19-mediated adhesion and into the biochemical basis of neurodevelopmental disease.

Sodium selenate is the first treatment with persistent disease-modifying effects reducing seizures and improving cognitive deficits, in chronically epileptic and drug-resistant TLE animals.

Multi-modal MRI techniques have identified biomarkers that could help to predict whether someone will develop epilepsy.